Gautam Rangavajla, Ritik Patel, Felix Nguyen, Brian Vickers, Omar Abdelhai, Brian La Starza, Karl Ilg, Waddah Maskoun, Matthew Ebinger, Marc Lahiri, Arfaat Khan, Josh Greenberg, Georgi Fram, Hussayn Alrayes, Leo Kar Lok Lai, Janet Wyman, Sachin Parikh, Bryan Zweig, John Dawdy, Nathaniel Bowerman, Pedro Engel Gonzalez, William O'Neill, Pedro Villablanca, James Lee, Brian P O'Neill, Mohamad Raad, Tiberio M Frisoli
{"title":"Atrioventricular Block After EVOQUE Transcatheter Tricuspid Valve Replacement.","authors":"Gautam Rangavajla, Ritik Patel, Felix Nguyen, Brian Vickers, Omar Abdelhai, Brian La Starza, Karl Ilg, Waddah Maskoun, Matthew Ebinger, Marc Lahiri, Arfaat Khan, Josh Greenberg, Georgi Fram, Hussayn Alrayes, Leo Kar Lok Lai, Janet Wyman, Sachin Parikh, Bryan Zweig, John Dawdy, Nathaniel Bowerman, Pedro Engel Gonzalez, William O'Neill, Pedro Villablanca, James Lee, Brian P O'Neill, Mohamad Raad, Tiberio M Frisoli","doi":"10.1016/j.shj.2025.100701","DOIUrl":null,"url":null,"abstract":"<p><p>•Based on a real-world study of 106 Evoque transcatheter tricuspid valve replacement (TTVR) recipients, a total of 14 (25%) cases of new atrioventricular (AV) block occurred after Evoque implantation in the 55 patients without prior pacemakers who met study inclusion criteria. This incidence is similar to that reported in the TRISCEND II clinical trial.•New AV block occurred in a median of 26 hours after Evoque TTVR (interquartile range: 5-60 hours), but there were cases of new AV block that occurred as late as 7 days after the procedure.•Of the 14 new cases of AV block, 12 were treated successfully with implantation of a leadless pacemaker (Micra) under fluoroscopic guidance without procedural complications or compromising the valve implantation.•The institutional strategy of 48-hour post-Evoque inpatient monitoring for all patients followed by mobile cardiac outpatient telemetry identified 11 of 14 cases of new AV block as before discharge from the hospital and 1 case as an outpatient before symptom onset.</p>","PeriodicalId":74878,"journal":{"name":"Structural heart : the journal of the Heart Team","volume":"9 9","pages":"100701"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357300/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Structural heart : the journal of the Heart Team","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.shj.2025.100701","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
•Based on a real-world study of 106 Evoque transcatheter tricuspid valve replacement (TTVR) recipients, a total of 14 (25%) cases of new atrioventricular (AV) block occurred after Evoque implantation in the 55 patients without prior pacemakers who met study inclusion criteria. This incidence is similar to that reported in the TRISCEND II clinical trial.•New AV block occurred in a median of 26 hours after Evoque TTVR (interquartile range: 5-60 hours), but there were cases of new AV block that occurred as late as 7 days after the procedure.•Of the 14 new cases of AV block, 12 were treated successfully with implantation of a leadless pacemaker (Micra) under fluoroscopic guidance without procedural complications or compromising the valve implantation.•The institutional strategy of 48-hour post-Evoque inpatient monitoring for all patients followed by mobile cardiac outpatient telemetry identified 11 of 14 cases of new AV block as before discharge from the hospital and 1 case as an outpatient before symptom onset.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
